Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Neurology

Why Are AQP4 and MOG Antibody Tests Used for RRMS?

At a Glance

AQP4-IgG and MOG-IgG blood tests are used when symptoms or MRI findings resemble MS but include red flags for NMOSD or MOGAD. Results must be interpreted with the clinical picture because treatment timing can cause false negatives and low-positive MOGAD results may not mean MOGAD.

In this answer

3 sections

01

Clinical “Red Flags”

02

How the Testing Works

03

Repeat Testing and Changes to Your Care Plan

When doctors evaluate possible relapsing-remitting multiple sclerosis (RRMS), they may order blood tests for AQP4-IgG and MOG-IgG antibodies to check for two distinct autoimmune conditions: Neuromyelitis Optica Spectrum Disorder (NMOSD) and MOG Antibody Disease (MOGAD) [1][2]. These conditions can closely mimic the symptoms and MRI findings of MS, but they are driven by different immune system targets [3]. It is crucial to distinguish them because their long-term treatment strategies differ [4]. Importantly, some common disease-modifying therapies used for MS can be ineffective for NMOSD or MOGAD, and some may even make AQP4-positive NMOSD worse [5][6].

Clinical “Red Flags”

Testing is not typically used to screen every MS patient, because indiscriminately testing people with classic MS increases the risk of misleading false-positive results [7][8]. Instead, doctors look for clinical “red flags” that suggest an alternative diagnosis. These clues include:

  • Severe or Bilateral Optic Neuritis: Inflammation of the optic nerve that affects both eyes simultaneously, causes severe vision loss, or fails to improve after standard steroid treatments [9][10].
  • Longitudinally Extensive Transverse Myelitis (LETM): Inflammation in the spinal cord that is exceptionally long. While a typical MS lesion spans a short distance, LETM spans across three or more contiguous vertebral segments (spinal bones) on an MRI [11][12].
  • Area Postrema Syndrome: Bouts of otherwise unexplained, intractable hiccups, nausea, or vomiting that last for at least 48 hours [13][14]. This happens when inflammation hits the area postrema, a specific part of the brainstem that controls the vomiting reflex [3].
  • Unusual Brain MRI Patterns: Brain lesions that do not fit the classic MS pattern, including large, poorly defined lesions or inflammation that mimics Acute Disseminated Encephalomyelitis (ADEM)—a condition causing widespread inflammation in the brain and spinal cord [15][16].

How the Testing Works

These tests look for specific disease-causing antibodies in your blood. For both conditions, the preferred testing method is a validated serum cell-based assay (CBA) [17][18]. This laboratory method uses live cells to see if your antibodies bind to the AQP4 or MOG proteins. Blood (serum) is generally more reliable than cerebrospinal fluid (CSF) for these tests, particularly for MOG-IgG [19][20].

However, antibody results are just one piece of the puzzle and must be interpreted alongside your symptoms and MRI scans [21]:

  • False positives from low levels: A “low-positive” result for MOG-IgG can sometimes occur in people without MOGAD, meaning a weak positive does not automatically guarantee a diagnosis [22][23].
  • False negatives from timing or treatment: Tests can come back negative if they are done while you are taking steroids, plasma exchange, intravenous immunoglobulin (IVIG), or other immunosuppressants, or if too much time has passed since an acute attack [20][24]. Ideally, blood is drawn before starting these treatments, though urgent treatment should never be delayed just to get a blood test [18].

Repeat Testing and Changes to Your Care Plan

If an initial test is negative but your doctor still strongly suspects NMOSD or MOGAD, they might recommend repeating the test under different circumstances, guided by the specific laboratory method used [20][25]. A negative test does not completely rule out these conditions, and a positive result alone does not finalize a diagnosis without matching clinical symptoms [21][1].

If an AQP4 or MOG antibody test comes back clearly positive and matches your clinical symptoms, your care plan will be adjusted. Acute, severe attacks for all these conditions are usually treated urgently with high-dose intravenous steroids, and severe NMOSD or MOGAD attacks often require early plasma exchange (a hospital procedure that filters antibodies from the blood) [18]. Note: Sudden or worsening vision loss, weakness, difficulty walking, breathing or swallowing problems, or persistent vomiting requires urgent medical evaluation.

For long-term relapse prevention, AQP4-positive NMOSD generally requires ongoing maintenance therapy using specific FDA-approved medications [4]. MOGAD treatment is highly individualized; because some people only ever have a single attack, long-term preventive medication may not be necessary for everyone, and treatments are often used off-label based on specialist assessment [2][26]. While waiting for test results, it is critical that you never stop, start, or change your current medications without direct instructions from your treating neurologist.

Quick Comparison

Feature Relapsing-Remitting MS AQP4-Positive NMOSD MOG Antibody Disease (MOGAD)
Typical Clues Short spinal cord lesions; Dawson’s fingers on brain MRI Long spinal cord lesions (LETM); intractable hiccups/nausea Severe or bilateral optic neuritis; ADEM-like brain inflammation
Primary Test MRI and clinical history; CSF oligoclonal bands Serum cell-based assay for AQP4-IgG Serum cell-based assay for MOG-IgG
Long-Term Prevention Standard MS disease-modifying therapies Targeted NMOSD medications (usually required long-term) Highly individualized; may not be required if only one attack occurs

Common questions in this guide

Why might my neurologist order AQP4 and MOG antibody tests if MS is suspected?
These blood tests look for antibodies associated with neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody disease (MOGAD), two conditions that can resemble multiple sclerosis. Telling them apart matters because their long-term treatments differ, and some MS medicines may not work for or may worsen AQP4-positive NMOSD.
What findings make AQP4 or MOG testing more likely?
Doctors may consider testing after severe or bilateral optic neuritis, a spinal cord lesion extending across three or more vertebral segments, or unexplained hiccups, nausea, or vomiting lasting at least 48 hours. Unusual brain MRI lesions, including acute disseminated encephalomyelitis-like inflammation, can also be a reason to test.
What is the most reliable way to test for AQP4 and MOG antibodies?
A validated serum cell-based assay is the preferred method for both tests, using a blood sample to see whether antibodies bind to the AQP4 or MOG proteins. Serum is generally more reliable than cerebrospinal fluid, especially for MOG-IgG.
Can treatment timing make an AQP4 or MOG test inaccurate?
Yes. Steroids, plasma exchange, intravenous immunoglobulin, and other immune-suppressing medicines can contribute to a negative result, as can testing long after an attack. Blood is ideally collected before treatment when possible, but urgent treatment should never be delayed to obtain the test.
Does a negative or weakly positive result settle the diagnosis?
No. A negative result does not completely rule out NMOSD or MOGAD, especially if testing occurred after treatment or long after an attack, and a low-positive MOG result can occur without MOGAD. Your neurologist should interpret the result with your symptoms and MRI findings and may recommend repeat testing.
How could a clearly positive result change my treatment?
A clearly positive result that matches your symptoms may shift the diagnosis and treatment plan away from standard MS care. Severe attacks are usually treated urgently with high-dose intravenous steroids, and severe NMOSD or MOGAD attacks may also need early plasma exchange; long-term prevention is usually ongoing for AQP4-positive NMOSD but individualized for MOGAD.

Related questions

What Diet and Vitamin D Supplements Are Best for RRMS? Can MS Be Diagnosed With a Normal Brain and Spine MRI? Can Relapsing-Remitting MS Progress Without Relapses? CIS vs. Relapsing-Remitting MS: What's the Difference? Does Relapsing-Remitting MS Reduce Life Expectancy?
Show more
How Do I Choose an MS Treatment Strategy for RRMS? How Is Relapsing-Remitting MS Distinguished From Migraine? How Is Secondary Progressive MS Diagnosed After RRMS? How Long Do Relapsing-Remitting MS Medications Take to Work? Is Relapsing-Remitting MS Hereditary? Risk & Testing Does RIS Become Relapsing-Remitting MS or Need Treatment? How Likely Is Another RRMS Relapse, and Can It Be Predicted? Which RRMS Treatment Schedule Fits My Lifestyle Best? Can I Exercise Safely With RRMS and Heat Sensitivity? What Do Oligoclonal Bands and KFLC Mean in MS Diagnosis? What Do the 2024 McDonald Criteria Mean for an MS Diagnosis? What Factors Affect Relapsing-Remitting MS Prognosis? When Should Disease-Modifying Treatment Start for RRMS? When Should I Seek a Second Opinion for RRMS Care?

Get notified when new evidence is published on relapsing-remitting multiple sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (26)
  1. 1

    Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.

    Jarius S, Aktas O, Ayzenberg I, et al.

    Journal of neurology 2023; (270(7)):3341-3368 doi:10.1007/s00415-023-11634-0.

    PMID: 37022481
  2. 2

    Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

    Flanagan EP, Hemingway C

    Continuum (Minneapolis, Minn.) 2026; (32(2)):481-512 doi:10.1212/cont.0000000000001678.

    PMID: 41925507
  3. 3

    Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria.

    Banwell B, Bennett JL, Marignier R, et al.

    The Lancet. Neurology 2023; (22(3)):268-282 doi:10.1016/S1474-4422(22)00431-8.

    PMID: 36706773
  4. 4

    Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD.

    Redenbaugh V, Flanagan EP

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2022; (19(3)):808-822 doi:10.1007/s13311-022-01206-x.

    PMID: 35267170
  5. 5

    CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications.

    Kaneko K, Sato DK, Nakashima I, et al.

    Journal of neurology, neurosurgery, and psychiatry 2018; (89(9)):927-936 doi:10.1136/jnnp-2018-317969.

    PMID: 29875186
  6. 6

    Treatment Approaches for MOG-Ab-Associated Demyelination in Children.

    Hacohen Y, Banwell B

    Current treatment options in neurology 2019; (21(1)):2 doi:10.1007/s11940-019-0541-x.

    PMID: 30671648
  7. 7

    MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.

    Jarius S, Paul F, Aktas O, et al.

    Journal of neuroinflammation 2018; (15(1)):134 doi:10.1186/s12974-018-1144-2.

    PMID: 29724224
  8. 8

    Frequency of AQP4 and MOG Antibodies in Patients With Optic Neuritis Fulfilling Minimal New Multiple Sclerosis MRI Criteria.

    Deschamps R, Papeix C, Demortiere S, et al.

    Neurology 2026; (106(7)):e214753 doi:10.1212/WNL.0000000000214753.

    PMID: 41843863
  9. 9

    An update on optic neuritis.

    Kraker JA, Chen JJ

    Journal of neurology 2023; (270(10)):5113-5126 doi:10.1007/s00415-023-11920-x.

    PMID: 37542657
  10. 10

    MOG antibody-associated optic neuritis.

    Jeyakumar N, Lerch M, Dale RC, Ramanathan S

    Eye (London, England) 2024; (38(12)):2289-2301 doi:10.1038/s41433-024-03108-y.

    PMID: 38783085
  11. 11

    The frequency of longitudinally extensive transverse myelitis in MS: A population-based study.

    Asnafi S, Morris PP, Sechi E, et al.

    Multiple sclerosis and related disorders 2020; (37()):101487 doi:10.1016/j.msard.2019.101487.

    PMID: 31707235
  12. 12

    Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.

    Dubey D, Pittock SJ, Krecke KN, et al.

    JAMA neurology 2019; (76(3)):301-309 doi:10.1001/jamaneurol.2018.4053.

    PMID: 30575890
  13. 13

    Immunobiology of neuromyelitis optica spectrum disorders.

    Mora Cuervo DL, Hansel G, Sato DK

    Current opinion in neurobiology 2022; (76()):102618 doi:10.1016/j.conb.2022.102618.

    PMID: 35973380
  14. 14

    Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein IgG associated disorder: A comprehensive neuro-ophthalmic review.

    Sharma J, Bhatti MT, Danesh-Meyer HV

    Clinical & experimental ophthalmology 2021; (49(2)):186-202 doi:10.1111/ceo.13863.

    PMID: 33426799
  15. 15

    Neuromyelitis Optica Spectrum Disorder with Tumefactive Demyelination mimicking Multiple Sclerosis: A Rare Case.

    Roy U, Saini DS, Pan K, et al.

    Frontiers in neurology 2016; (7()):73 doi:10.3389/fneur.2016.00073.

    PMID: 27242658
  16. 16

    The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.

    Qin C, Chen B, Tao R, et al.

    Multiple sclerosis and related disorders 2019; (35()):1-4 doi:10.1016/j.msard.2019.06.035.

    PMID: 31276911
  17. 17

    Real-world clinical experience with serum MOG and AQP4 antibody testing by live versus fixed cell-based assay.

    Said Y, Filippatou A, Tran C, et al.

    Annals of clinical and translational neurology 2025; (12(3)):556-564 doi:10.1002/acn3.52310.

    PMID: 39901660
  18. 18

    Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines.

    Yamout B, Gouider R, Al-Roughani R, et al.

    CNS drugs 2026; (40(3)):283-303 doi:10.1007/s40263-025-01260-x.

    PMID: 41591715
  19. 19

    The clinical relevance of MOG antibody testing in cerebrospinal fluid.

    Reynolds M, Tan I, Nguyen K, et al.

    Annals of clinical and translational neurology 2024; (11(9)):2514-2519 doi:10.1002/acn3.52163.

    PMID: 39073255
  20. 20

    Use of Fluid Biomarkers in NMOSD and MOGAD: Clinical and Research Applications.

    Mariotto S, Cobo-Calvo A, Khalil M, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2026; (13(5)):e200627 doi:10.1212/NXI.0000000000200627.

    PMID: 42579841
  21. 21

    Timing of MOG-IgG Testing Is Key to 2023 MOGAD Diagnostic Criteria.

    Forcadela M, Rocchi C, San Martin D, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2024; (11(1)) doi:10.1212/NXI.0000000000200183.

    PMID: 37977848
  22. 22

    The positive predictive value of MOG-IgG testing based on the 2023 diagnostic criteria for MOGAD.

    Nguyen L, Singh S, Feltrin FS, et al.

    Multiple sclerosis journal - experimental, translational and clinical 2024; (10(3)):20552173241274610 doi:10.1177/20552173241274610.

    PMID: 39148657
  23. 23

    Positive Predictive Value of MOG-IgG for Clinically Defined MOG-AD Within a Real-World Cohort.

    Manzano GS, Salky R, Mateen FJ, et al.

    Frontiers in neurology 2022; (13()):947630 doi:10.3389/fneur.2022.947630.

    PMID: 35795797
  24. 24

    Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria.

    Fadda G, Waters P, Woodhall M, et al.

    Multiple sclerosis (Houndmills, Basingstoke, England) 2022; (28(11)):1697-1709 doi:10.1177/13524585221093789.

    PMID: 35581944
  25. 25

    Frequency of Seroconversion in Aquaporin-4 Antibody Testing: Insights From Real-World Data.

    Ongphichetmetha T, Du M, Vorasoot N, et al.

    Annals of clinical and translational neurology 2025; (12(10)):2158-2163 doi:10.1002/acn3.70185.

    PMID: 40959895
  26. 26

    Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management.

    Sechi E, Cacciaguerra L, Chen JJ, et al.

    Frontiers in neurology 2022; (13()):885218 doi:10.3389/fneur.2022.885218.

    PMID: 35785363

This page is for informational purposes only and does not constitute medical advice. Your neurologist or neuroimmunology specialist should interpret AQP4 and MOG results alongside your symptoms, MRI findings, and treatment history.